Northwest Biotherapeutics, Inc. (NWBO)
OTCMKTS · Delayed Price · Currency is USD
0.2040
-0.0010 (-0.49%)
At close: Jun 3, 2026
Northwest Biotherapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 1.79 | 3.04 | 2.18 | 2.13 | 6.97 | 15.17 |
Cash & Short-Term Investments | 1.79 | 3.04 | 2.18 | 2.13 | 6.97 | 15.17 |
Cash Growth | -35.73% | 39.77% | 2.31% | -69.48% | -54.08% | 51.95% |
Receivables | - | 0.31 | - | - | - | - |
Prepaid Expenses | 4.42 | 2.17 | 1.89 | 2 | 2.46 | 2.12 |
Total Current Assets | 6.2 | 5.52 | 4.06 | 4.13 | 9.43 | 17.29 |
Property, Plant & Equipment | 20.82 | 21.6 | 20.38 | 21.46 | 19.64 | 19.92 |
Goodwill | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 |
Other Intangible Assets | 52.05 | 53.19 | 1.29 | 1.29 | 1.29 | 1.29 |
Other Long-Term Assets | 0.35 | 0.36 | 0.37 | 0.36 | 0.35 | 1.04 |
Total Assets | 80.05 | 81.29 | 26.73 | 27.87 | 31.32 | 40.16 |
Accounts Payable | 31.58 | 30.82 | 16.97 | 10.24 | 10.69 | 6.98 |
Accrued Expenses | - | - | 4.45 | - | - | - |
Short-Term Debt | 11.65 | 9.47 | 14.19 | 3.94 | 15.4 | 7.1 |
Current Portion of Long-Term Debt | 31.57 | 32.7 | 20.19 | 16.54 | 0.14 | 0.14 |
Current Portion of Leases | 0.27 | 0.37 | 0.33 | 0.31 | 0.35 | 0.32 |
Other Current Liabilities | 7.9 | 18.35 | 12.15 | 14.17 | 99.43 | 119.24 |
Total Current Liabilities | 82.97 | 91.7 | 68.27 | 45.2 | 126.01 | 133.77 |
Long-Term Debt | 16.21 | 17.88 | 28.3 | 20.31 | 5.99 | 25.16 |
Long-Term Leases | 4.29 | 4.41 | 4.44 | 4.45 | 4.37 | 5.23 |
Long-Term Deferred Tax Liabilities | 12.94 | 13.17 | - | - | - | - |
Other Long-Term Liabilities | 1.7 | 1.7 | 4.7 | 4.95 | - | - |
Total Liabilities | 118.11 | 128.86 | 105.71 | 74.92 | 136.37 | 164.15 |
Common Stock | 1.62 | 1.57 | 1.33 | 1.18 | 1.07 | 0.95 |
Additional Paid-In Capital | 1,455 | 1,443 | 1,345 | 1,291 | 1,165 | 1,067 |
Retained Earnings | -1,507 | -1,504 | -1,443 | -1,360 | -1,297 | -1,192 |
Treasury Stock | -0.01 | -0.01 | - | - | - | - |
Comprehensive Income & Other | -0.51 | -1 | 2.96 | 1.46 | 3.07 | 0.28 |
Total Common Equity | -50.54 | -60.28 | -94.49 | -65.77 | -128.1 | -123.99 |
Shareholders' Equity | -38.06 | -47.57 | -78.98 | -47.06 | -105.04 | -123.99 |
Total Liabilities & Equity | 80.05 | 81.29 | 26.73 | 27.87 | 31.32 | 40.16 |
Total Debt | 63.99 | 64.83 | 67.44 | 45.56 | 26.25 | 37.94 |
Net Cash (Debt) | -62.21 | -61.79 | -65.27 | -43.43 | -19.29 | -22.77 |
Net Cash Per Share | -0.04 | -0.04 | -0.05 | -0.04 | -0.02 | -0.02 |
Filing Date Shares Outstanding | 1,643 | 1,607 | 1,391 | 1,190 | 1,073 | 960.02 |
Total Common Shares Outstanding | 1,607 | 1,567 | 1,329 | 1,176 | 1,068 | 948.45 |
Working Capital | -76.77 | -86.18 | -64.21 | -41.08 | -116.58 | -116.48 |
Book Value Per Share | -0.03 | -0.04 | -0.07 | -0.06 | -0.12 | -0.13 |
Tangible Book Value | -103.22 | -114.09 | -96.41 | -67.69 | -130.02 | -125.91 |
Tangible Book Value Per Share | -0.06 | -0.07 | -0.07 | -0.06 | -0.12 | -0.13 |
Land | 0.09 | 0.09 | 0.09 | 0.09 | 0.08 | 0.09 |
Machinery | 5.91 | 5.92 | 3.69 | 3.26 | 2.54 | 2.11 |
Construction In Progress | - | - | - | - | 2.03 | - |
Leasehold Improvements | 18.92 | 19.08 | 17.97 | 17.79 | 13.07 | 13.91 |